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Abstract
Background: Transcranial duplex sonography (TCD) of the substantia nigra has emerged as a
promising, non-invasive tool to diagnose idiopathic Parkinson's disease (IPD). However, its
diagnostic accuracy in patients with undefined parkinsonism remains to be determined.
In this study we determined the predictive value of TCD for the clinical diagnosis in undiagnosed
parkinsonian syndromes. Additionally we compared the predictive value of TCD with that of
presynaptic and postsynaptic single photon emission computer tomography (SPECT) scans.
Methods: We studied 82 patients with an unclassified parkinsonian syndrome. All 82 patients were
subjected to a TCD, 59 of them underwent a presynaptic SPECT scans and 32 underwent a
postsynaptic SPECT scan.
We determined the diagnostic accuracy of TCD and SPECT scans in differentiating:
1) IPD patients from patients without nigrostriatal degeneration and 2) IPD patients from patients
with atypical parkinsonian syndromes (APS).
To compare the diagnostic accuracy of TCD and SPECT scans, we used the clinical diagnosis after
follow-up according to generally accepted clinical criteria as the gold standard. This clinical
diagnosis was determined by a movement disorder specialist.
3) Finally, we ascertained the predictive value of the TCD for the SPECT result.
Results: The clinical diagnoses after follow-up resulted in 51 cases of IPD, 7 patients with APS and
17 patients without nigrostriatal degeneration. In total 7 patients remained undiagnosed.
1) The accuracy of TCD, assessed by sensitivity and specificity, to differentiate IPD patients from
patients without nigrostriatal degeneration was 50% and 82% respectively.
For the presynaptic SPECT scans sensitivity was 97% and specificity 100%.
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and 43% respectively. For presynaptic SPECT scans this was 97% and 0%. For the postsynaptic
SPECT scans the sensitivity was 75% and the specificity 81%.
3) The positive predictive value (PPV) of an abnormal TCD for an abnormal presynaptic SPECT
scan was 88%.
Conclusion: Presynaptic SPECT scanning has a higher predictive value for the clinical diagnosis
than TCD. However, since the PPV of an abnormal TCD for parkinsonism with nigrostriatal
degeneration is high, TCD might be used as screening tool, before ordering a presynaptic SPECT.
Background
The diagnosis of idiopathic Parkinson's disease (IPD) is
based on clinical criteria. When cardinal clinical signs and
symptoms as bradykinesia, rigidity, and resting tremor are
present, the diagnosis of IPD is straightforward [1]. How-
ever, the differentiation between IPD and other parkinso-
nian syndromes can be difficult, especially in the early
stages of the disease.
Diseases which might resemble early-stage IPD are Multi-
ple System Atrophy (MSA), Progressive Supranuclear
Palsy (PSP), Diffuse Lewy Body Disease (DLBD), cortico-
basal degeneration (CBD), but also vascular parkinson-
ism (VP), drug induced parkinsonism (DIP) and essential
tremor (ET). Clinicopathological studies show that 2–
25% of the patients with IPD are classified incorrectly in
the final stage of their disease, even by specialists in move-
ment disorders [2-6]. Because the prognosis and medical
treatment differ between various parkinsonian syn-
dromes, an accurate and early diagnosis is essential for
optimal treatment and counselling.
Single Photon Emission Computer Tomography (SPECT),
with presynaptic and postsynaptic radiotracers, is widely
used in the diagnostic work-up of patients with parkinso-
nian syndromes. Despite its widespread use, the exact
diagnostic accuracy of this technique in parkinsonian syn-
dromes remains somewhat controversial [7,8].
Becker and colleagues were first to report hyperechointen-
sity of the substantia nigra (SN) in patients with IPD by
using transcranial duplex sonography (TCD) [9]. Several
studies found that this increased SN echointensity is
present in 90% of IPD patients [9-12], presumably caused
by a local increased iron content [13,14]. In healthy indi-
viduals this increased SN echointensity is found in only
9% [15]. Since Becker's first report, roughly 70 studies on
the diagnostic accuracy of TCD in parkinsonian syn-
dromes have been published. Most studies on TCD and
IPD have been done on later-stage, well-diagnosed
patients. However, this does not resemble the situation in
clinical practice, where the neurologist would want to use
TCD to reach a diagnosis in patients with a clinically
unclear parkinsonisme.
In the present study we assessed the diagnostic accuracy of
TCD of the SN (SN-TCD) in 82 consecutive patients with
a recent, as yet unclassified, parkinsonian syndrome. We
compared the diagnostic accuracy of SN-TCD with that of
SPECT scan, which was done simultaneously in most of
these patients. We also calculated the predictive value of
the SN-TCD for the results of the SPECT scans.
Methods
Patients
We retrospectively studied 82 consecutive patients who
presented at our outpatient clinic with a parkinsonism of
yet unknown origin. All of these patients were subjected
to a SN-TCD between 2004 – 2006 after giving their
informed consent. The study was approved by the Institu-
tional Review Board (committee for Medical Ethics) of the
University Hospital Maastricht.
We initially studied 95 patients, of whom we had to
exclude 13 (15%) with inconclusive SN-TCD's because of
an inappropriate temporal bone window (i.e. insufficient
to acquire a 2-dimensional image of the intracranial struc-
tures). This percentage of inconclusive results is within the
normal range [15-17].
Of the 82 patients, 59 underwent presynaptic-SPECT
imaging and 32 postsynaptic SPECT imaging depending
on the personal judgement of the treating specialist (Fig-
ure 1).
To reach a clinical diagnosis (the surrogate gold standard
in this study) the patients were re-examined by an inde-
pendent neurologist specialised in movement disorders,
after an interval of at least six months.
A total of 52 patients (63%) gave consent to be re-exam-
ined (21 refused re-examination, 5 patients died, and 4
were lost to follow-up). However, the clinical records of
the 30 patients that were not actually re-examined, werePage 2 of 8
(page number not for citation purposes)
BMC Neurology 2008, 8:42 http://www.biomedcentral.com/1471-2377/8/42studied by the experts (WW, AW). They tried to reach a
final clinical diagnosis for these patients, according to
generally accepted clinical criteria.[1,3,18-21] If there was
clinical doubt between different parkinsonian disorders a
patient was called "undiagnosed".
SN-TCD
We used a 2–4 MHz phased array transducer on a com-
mercially available ultrasound system (SONOS 5500;
Philips, Eindhoven, the Netherlands). The transducer was
placed over the transtemporal bone window and focussed
at a depth of 6–8 cm to allow for optimal image quality of
the brainstem. Overall gain and the degree of compres-
sion were visually adapted to optimally depict an
increased echointensity of the SN, if present. In practice a
relatively high gain setting was used in combination with
relatively little compression. This combination resulted in
an almost homogeneously echolucent brainstem for the
areas where no increase of the echointensity can be
expected. The Raphe nuclei, the nucleus ruber and the SN
(in case of a positive finding) on the other hand were eas-
ily distinguishable due to their increased echointensity.
All other parameters like time gain compensation, post-
processing and power settings were kept constant
throughout the study.
Flowchartigure 1
Flowchart. N: number of patients, TCD: transcranial duplex, SPECT single photon emission computer tomography, IPD: idio-
pathic Parkinson's disease, APS: atypical parkinsonian syndromes, ET: essential tremor, VP: vascular parkinsonism, DIP: drug 
induced parkinsonism, restgroup: two patients had spontaneous disappeared parkinsonism, 1 normal pressure hydrocephalus 
and 1 frontotemporal dementia.
n= 95























Diagnosis after follow-up: 75 patients diagnosed: 51 IPD 5 VP
7 APS 4 DIP
2 ET 6 restgroup
7 patients undiagnosedPage 3 of 8
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(insonation frequency 1.8 MHz). Yet it appeared, that
with our ultrasound system we were able to visualize the
brainstem only in a minority of patients. Since it is also
well-known (personal conversation with Prof. D. Berg,
Tübingen), that second harmonic imaging will lead to an
increase of the hyperechointense area of the SN if com-
pared to images based on the basal frequency content, we
decided to use only primary images in this study.
A loop of 64 images was acquired by scanning the brain-
stem cranio-caudally through the pre-auricular bone win-
dow on the both sides. The images were stored digitally to
allow for off-line analysis by a second sonographer. Both
sonographers were blinded for the SPECT results and the
clinical diagnoses. The echointensity of the SN was evalu-
ated by ipsilateral insonation.
The SN echointensity can be estimated semi-quantitatively
by manually encircling the area of hyperechointensity and
having the ultrasound system measuring the area [10,15].
In our experience it is often difficult to accurately delineate
the area of the SN hyperechointensity (if present), which
would lead to inconsistent results. Therefore, we used a
simplified and more practical method using the following
qualitative scores: "positive", "negative", "inconclusive". Com-
parable qualitative scoring systems have also been used by
other investigator groups [22-24].
The SN-TCD is scored "positive", when, at least on one side,
the SN is clearly visible due to its increased echointensity as
compared to the surrounding brainstem tissue. Addition-
ally, the hyperechointense area has to correspond with the
anatomy of the SN. Only if the hyperechointense area
extends as an oblique and continuous band in the medial-
anterior to lateral-posterior direction, we scored this as a
"positive" finding. We could show that such an echo inten-
sity increase always corresponded to an area larger than 0.2
cm2 (unpublished data; currently under review).
If the image quality is sufficient to evaluate the echointensity
of the SN, but the above mentioned criteria are not met, then
the SN-TCD is scored "negative". This implies, that an SN-
TCD is also called "negative" if there is a doubtful hyperech-
ointensity. This could be either due to an atypical anatomical
distribution or only a small area of hyperechointensity not
extending throughout the whole brainstem in the horizontal
plane as described above. An "inconclusive" SN-TCD is a
measurement where visualization of the intracranial struc-
tures is not or only partly possible due to insufficient tempo-
ral bone windows on both sides.
SPECT
In this study we used the presynaptic radiotracer FP-CIT
(123I-Ioflupane, General Electrics Health, Eindhoven,
The Netherlands) and the postsynaptic tracer IBZM (123I-
iodobenzamide, General Electrics Health, Eindhoven, The
Netherlands). Medication which could interfere with the
radiotracer was stopped at least 5 half-life times before the
SPECT was made. SPECT scans were performed with a tri-
ple head camera (MultiSPECT3, Siemens, Ohio, USA)
equipped with high-resolution collimators. A semi-auto-
matic template model programme was used to calculate
the ratios between left striatal and right striatal and occip-
ital regions, respectively. Total time of acquisition was 30
minutes (45 seconds per frame for 40 views per detector),
zoom factor: 1.00 and the matrix size: 128 × 128. Filtered
back-projection acquisition was performed. Images were
filtered using a Butterworth filter with a cut-off value of
0.4–0.5 and an order of 5. The ratios were corrected using
Alderson's brain phantom with known activities in the
caudate nucleus and putamen.
A binding of two standard deviations below healthy con-
trols was considered as abnormal (FP CIT 8.25, sd 1.85 for
putamen and 7.76, sd 1.77 for caudate nucleus. IBZM for
striatum 3.58, sd 0.18). The scans were analysed by a
nuclear medicine specialist who was blinded for the clin-
ical diagnosis and the SN-TCD results.
Statistics
The diagnostic accuracy of SN-TCD, presynaptic and post-
synaptic SPECT scintigraphy was determined by compar-
ing their results to the surrogate gold standard: the clinical
diagnosis after follow-up. Diagnostic accuracy is defined
as the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV).
The accuracy was determined for: 1) IPD patients and
patients without nigrostriatal degeneration (ET, DIP, VP,
restgroup) and 2) IPD and APS patients.
And finally, we calculated the predictive value of SN-TCD
for the presynaptic and postsynaptic SPECT result. SPSS
(SPSS, Chicago, IL) was used for statistical analysis.
Results
Descriptives
The mean (standard deviation [SD]) age of the 82 patients
was 69 (10) years, and the majority (65%) was male. The
mean (SD) Hoehn and Yahr score was 2.4 (1.1). The fol-
low-up duration after the SN-TCD was on average 17 (10)
months.
In 75 (91%) of the 82 cases, it was possible for the move-
ment disorders specialist to come to a definite clinical
diagnosis. Seven cases remained undiagnosed after fol-
low-up, because they did not fulfil the generally accepted
clinical criteria [1,3,18-21]. For an overview of all the clin-
ical diagnoses after follow-up see Table 1.Page 4 of 8
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For the complete overview of the results of the SN-TCD,
presynaptic and postsynaptic SPECT in each subgroup of
patients, see Table 1.
The sensitivity of the SN in differentiating patients with
IPD (n = 51) from patients with ET, VP, DIP or the rest
group (n = 17) was 50%, while the specificity was 82%,
the PPV 89% and the NPV 35%. For the presynaptic
SPECT scans these values were respectively 97%, 100%,
100% and 92%.
SN-TCD could differentiate IPD patients (n = 51) from
APS (n = 7) patients with a sensitivity of 50%, the specifi-
city 43%; the PPV and the NPV were 86% and 10%,
respectively. For the presynaptic SPECT scans, these values
were 97%, 0%, 86% and 0% respectively, while for the
postsynaptic SPECT the were 75%, 81%, 43% and 94%.
Of the 7 APS patients, 4 had a positive SN-TCD, while all
7 had an abnormal presynaptic SPECT. All 7 IPD and APS
patients with an abnormal postsynaptic SPECT also had a
significantly lowered presynaptic SPECT scan.
When the second sonographer (ST) assessed the SN-TCD,
she obtained similar results in the vast majority of the
patients (92%).
Predictive value of SN-TCD for the results of the SPECT 
scan
59 patients underwent presynaptic SPECT imaging (see
Table 2). In 33 patients (56%), the result of the SN-TCD
was in line with the result of the presynaptic SPECT scan.
The PPV of a positive SN-TCD for an abnormal SPECT was
high: 88%. However, the NPV of a negative SN-TCD for a
normal presynaptic SPECT was only 30%.
32 patients underwent postsynaptic SPECT imaging (see
Table 3). In 14 (44%) of the 32 cases, the result of the SN-
TCD was in line with the result of the postsynaptic SPECT
scan. The PPV of a positive SN-TCD for an abnormal post-
synaptic SPECT was 29% and the NPV 73%.
Discussion
Since the first report by Becker et al in 1995, SN hypere-
chogenicity in patients with IPD has been confirmed by
many researchers [9,16,25-28]. These investigators have
suggested that SN-TCD is an accurate instrument in dis-
criminating IPD patients from normal healthy subjects,
and from patients with other types of parkinsonism. How-
ever, most studies on TCD of the SN involve groups of
well-diagnosed IPD patients, in the later stages of the dis-
ease. The diagnostic accuracy of SN-TCD in early-stage
patient populations, with less well-defined clinical syn-
dromes, thus remains to be determined. In an effort to do
this, we did SN-TCD in 82 undiagnosed parkinsonian
patients. As the gold standard for the patient's final diag-
nosis, we chose the clinical diagnosis after follow-up. This
is, of course, not as good as post-mortem neuropatholog-
ical analysis, but the best possible alternative at present.
In our study, the diagnostic accuracy of presynaptic SPECT
is superior to that of SN-TCD. Especially the sensitivity
and NPV in differentiating patients with parkinsonism
with nigrostriatal degeneration (IPD, MSA, PSP, DLBD,









IPD n = 51 25 of 51 37 of 38 4 of the 21
APS n = 7 4 of 7 6 of 6 3 of 4
• MSA n = 2 2 of 2 1 of 1 1 of 1
• PSP n = 2 1 of 2 2 of 2 1 of 1
• CBD n = 2 0 of 2 2 of 2 1 of 1
• DLBD n = 1 1 of 1 1 of 1 0 of 1
ET n = 2 0 of 2 0 of 2 -
VP n = 5 2 of 5 0 of 4 2 (visually 0) of 3
DIP n = 4 0 of 4 0 of 1 -
rest group n = 6a 1 of 6 0 of 4 0 of 1
undiagnosed n = 7b 3 of 7 3 of 4 1 of 3
n = 82 n = 82 N = 59 n = 32
n: number of patients, SN-TCD: transcranial duplex of the substantia nigra, SPECT: Single Photon Emission Computer tomography, IPD idiopathic 
Parkinson's disease, APS atypical parkinsonian syndromes, MSA multiple system atrophy, PSP progressive supranuclear paralysis, CBD cortical basal 
degeneration, DLBD diffuse Lewy body disease, ET essential tremor, VP vascular parkinsonism, DIP drug induced parkinsonism,
a: restgroup: two patients had spontaneous disappeared parkinsonism, 1 normal pressure hydrocephalus, 1 frontotemporal dementia.
b: undiagnosed: a patient was called undiagnosed if it was not possible to draw a conclusion on the final diagnosis according to generally accepted 
clinical criteria. [1,3,18-21]Page 5 of 8
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higher in presynaptic SPECT than in SN-TCD. However,
the PPV of a positive SN-TCD for parkinsonism with
nigrostriatal degeneration is high. This means that,
although not all patients with nigrostriatal degeneration
have a positive SN-TCD, a positive SN-TCD is a good pre-
dictor in diagnosing parkinsonism with nigrostriatal
degeneration.
In our study, we also investigated the similarity in results
between SN-TCD and presynaptic SPECT. We found a
high PPV (88%) of a positive SN-TCD for an abnormal
SPECT result, confirming other reports [29]. For clinical
practice, this would imply that a positive SN-TCD in a
patient with an early-stage, recently diagnosed parkinso-
nian syndrome, would reduce the added diagnostic value
of a presynaptic SPECT.
A striking difference between ours and other studies, is the
percentage of false-negative IPD patients diagnosed by
SN-TCD. Our 50% is much higher than the 0–20%
reported by other investigators [9,16,25-28]. There are
several explanations for our lower sensitivity rate. Firstly,
we used a broad spectrum of parkinsonian patients, which
is representative for the diagnostic problem that one
wants to solve. Other studies with similarly mixed patient
groups also found a lower accuracy of the SN-TCD
[22,23,30]. Secondly, our sonographers were blinded to
the results of the clinical diagnosis. This might also have
led to a decreased sensitivity of the SN-TCD, since we con-
sidered the SN-TCD negative in cases where we had
doubts about the level of hyperechointensity. Thirdly, our
patient population had a relatively large number of
patients in the early stages of their disease. Although Berg
et al. reported SN echointensity to be stable during follow-
up, the question remains whether this is also the case in
early-stage patient populations [31]. Fourthly, the quality
of the ultrasound system is a non-neglectable variable,
since in our pilot experiments, we found that the newest
ultrasound systems will reveal hyperechointensity of the
SN in more patients [32]. Finally, the TCD technique itself
can provide an explanation. One needs considerable per-
sonal expertise to perform and interpret a TCD correctly.
Since the pioneering research group in Tübingen has built
up an enormous amount of expertise, it will be difficult
for other groups to reproduce their excellent diagnostic
results [25,32-37].
In summary, our study with early-stage parkinsonian
patients, shows that the specificity and the PPV of SN-TCD
for the final clinical diagnosis is just as high as it is for the
SPECT scans. The sensitivity of the SN-TCD in our patient
population is significantly lower than that of presynaptic
SPECT scans. So in this population, the SN-TCD might be
used as screening instrument: one could argue that in
patients where the SN-TCD is compatible with parkinson-
ism with nigrostriatal degeneration, a presynaptic SPECT
is no longer necessary in the diagnostic work-up. Applying
this strategy, in our group of patients, 35% SPECT scans
could have been omitted, resulting in a significant reduc-
tion in costs. Besides this, SN-TCD is also a more patient-
friendly technique than SPECT scans.
Conclusion
Our study with early-stage parkinsonian patients shows
that the diagnostic accuracy of presynaptic SPECT scans is
Table 2: Contingency of the 59 patients who underwent both SN-TCD and presynaptic SPECT imaging
Total number of patients n = 59 presynaptic SPECT abnormal presynaptic SPECT normal
SN-TCD positive (= abnormal) 23a 3c
SN-TCD negative (= normal) 23b 10d
SN substantia nigra, TCD transcranial duplex, SPECT Single Photon Emission Computer Tomography
a: n = 23 19 PD, 3 APS, 1 undiagnosed
b: n = 23 18 PD, 3 APS (2 CBD, 1 PSP), 2 undiagnosed
c: n = 3 2 VP, 1 spontaneous disappeared parkinsonism
d: n = 10 1 PD, 2 VP, 2 ET, 1 DIP, 3 rest group, 1 undiagnosed
Table 3: Contingency of the 32 patients who underwent both SN-TCD and postsynaptic SPECT imaging
Total number of patient n = 32 postsynaptic SPECT abnormal postsynaptic SPECT normal
SN-TCD positive (= abnormal) 6a 15c
SN-TCD negative (= normal) 3b 8d
SN substantia nigra, TCD transcranial duplex, SPECT Single Photon Emission Computer Tomography
a: IPD 2, APS 2, inconclusive 2
b: IPD 2, APS 1
c: IPD 13, APS 1, inconclusive 1
d: IPD 4, VP 3, 1 restgroupPage 6 of 8
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the PPV of SN-TCD for the final clinical diagnosis, are
almost as high as for presynaptic SPECT scans. So in this
population, the SN-TCD might be used as screening
instrument: patients with a SN-TCD compatible with par-
kinsonism with nigrostriatal degeneration would not
need a presynaptic SPECT.
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